Skip to content
Search

Latest Stories

UK govt to invest £100 million for developing AI-powered solutions to overcome healthcare challenges

The new funding for AI could accelerate the development of novel dementia therapies.  

The UK Government is investing £100 million to accelerate the use of AI in life sciences and healthcare under a new mission.


UK Prime Minister Rishi Sunak announced the AI Life Sciences Accelerator Mission in his speech last week.

The new initiative will capitalise on the UK’s unique strengths in securing “health data and cutting-edge AI.”

It will also help to identify those at risk of “dementia” and will ensure that patients participate in the trials at the right time to develop new treatments effectively.

Henceforth, it will provide us with better data on how well new therapies work.

Sunak said: “AI can help us solve some of the greatest social challenges of our time. AI could help find novel dementia treatments or develop vaccines for cancer.”

“That’s why today we’re investing a further £100 million to accelerate the use of AI on the most transformational breakthroughs in treatments for previously incurable diseases,” he added.

Secretary of State for Science, Innovation and Technology Michelle Donelan said: “Safe, responsible AI will change the game for what it’s possible to do in healthcare, closing the gap between the discovery and application of innovative new therapies, diagnostic tools, and ways of working that will give clinicians more time with their patients.”

The government will collaborate with industry, the NHS, academia and medical research charities to achieve the Life Sciences Vision that includes eight critical healthcare missions – from cancer treatment to tackling dementia.

Moreover, the £100 million funding will explore how AI is tackling these health conditions, which are associated with some of the highest mortality and morbidity rates.

Within the next 18 months, this initiative will enable us to allocate resources to regions in the UK with the most pressing clinical needs for testing and implementing new technologies.

It is estimated that in the next five years, AI will transform “mental health research through developing world-class data infrastructure to improve the lives of those living with mental health conditions.”

Furthermore, it highlighted that the funding will target opportunities to “deploy AI in clinical settings and improve health outcomes across a range of conditions.”

It will also seek to fund innovative AI research that can produce general-purpose applications, allowing clinicians to dedicate more time to their patients.

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less